Phase IIa clinical trial in which 75 non-ICU hospital inpatients will be randomized 2:1 to 7
days of an oral formulation of cyclosporine, Neoral (2.5mg/kg PO BID) + standard of care
(SOC) or no Neoral + SOC. The primary endpoint is disease severity based on the World Health
Organization (WHO) COVID Ordinal Outcomes Scale, on day 14. Secondary endpoints include
safety and changes in serum inflammatory markers.